Philip Nickson
General Counsel bei MONTE ROSA THERAPEUTICS, INC.
Vermögen: - $ am 30.04.2024
Profil
Philip Nickson is currently working as the General Counsel at Monte Rosa Therapeutics, Inc. He previously worked as the Vice President-Intellectual Property at Momenta Pharmaceuticals, Inc. from 2012 to 2021.
Dr. Nickson holds a doctorate degree from The University of Manchester and a graduate degree from Suffolk University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 02.01.2024 | 0 ( -.--% ) | - $ | 30.04.2024 |
Aktive Positionen von Philip Nickson
| Unternehmen | Position | Beginn |
|---|---|---|
| MONTE ROSA THERAPEUTICS, INC. | General Counsel | 01.03.2021 |
Ehemalige bekannte Positionen von Philip Nickson
| Unternehmen | Position | Ende |
|---|---|---|
| MOMENTA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.03.2021 |
Ausbildung von Philip Nickson
| Suffolk University | Graduate Degree |
| The University of Manchester | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| MONTE ROSA THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Momenta Pharmaceuticals, Inc.
 Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
